Silke Kern1,2,3, Jeremy A Syrjanen1, Kaj Blennow2,4, Henrik Zetterberg2,4,5,6, Ingmar Skoog2,3, Margda Waern2,3, Clinton E Hagen1, Argonde C van Harten7,8, David S Knopman7, Clifford R Jack9, Ronald C Petersen7, Michelle M Mielke1,7. 1. Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 2. Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. 3. University of Gothenburg, Mölndal, Sweden. 4. Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. 5. Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the Institute of Neurology, University College London, Queen Square, London, England. 6. United Kingdom Dementia Research Institute at University College London, London, England. 7. Department of Neurology, Mayo Clinic, Rochester, Minnesota. 8. Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands. 9. Department of Radiology, Mayo Clinic, Rochester, Minnesota.
Abstract
Importance: Accumulating data suggest that elevated cerebrospinal fluid (CSF) neurofilament light (NfL) and neurogranin (Ng) levels are associated with cognitive decline and may be useful markers of neurodegeneration. However, to our knowledge, previous studies have not assessed these CSF markers in the community, evaluated them with regards to risk of mild cognitive impairment (MCI), or compared their prognostic value with CSF total tau (T-tau) or phosphorylated tau (P-tau). Objective: To determine (1) whether CSF NfL and Ng levels were associated with risk of MCI, (2) the effect size of these markers compared with CSF T-tau or P-tau for risk of MCI, and (3) whether CSF amyloid-β (Aβ42) modified these associations. Design, Setting and Participants: The analyses included 648 participants without cognitive impairment who were enrolled into the prospective population-based Mayo Clinic Study of Aging between January 2004 and December 2015 with available CSF data and at least 1 follow-up visit. Participants were followed up for a median of 3.8 years (interquartile range, 2.6-5.4 years). The CSF NfL and Ng levels were measured using an in-house sandwich enzyme-linked immunosorbent assay. The CSF Aβ42, T-tau, and P-tau levels were measured with automated electrochemiluminescence immunoassays. Cox proportional hazards models, with age as the timescale, were used to assess the association between CSF NfL, Ng, Aβ42, T-tau, or P-tau with risk of MCI after adjusting for sex, education, apolipoprotein E genotype, and the Charlson comorbidity index. To examine CSF Aβ42 as an effect modifier, it was categorized into tertiles; the bottom tertile was defined as having elevated brain amyloid. Main Outcomes and Measures: Risk of MCI. Results: At baseline, the median age of the 648 participants without cognitive impairment was 72.3 years (range, 50.7-95.3 years) and 366 (56.5%) were men; 96 (14.8%) developed incident MCI. Compared with the bottom quartile, the top quartile of CSF NfL was associated with a 3.1-fold increased risk of MCI (hazard ratio, 3.13; 95% CI, 1.36-7.18) in multivariate models. Neither CSF T-tau, P-tau, nor Ng was associated with risk of MCI. There was no interaction between Aβ42 and CSF NfL for risk of MCI. Conclusions and Relevance: Elevated CSF NfL levels but not CSF T-tau, P-tau or Ng are a risk factor for MCI in a community population and are independent of brain amyloid.
Importance: Accumulating data suggest that elevated cerebrospinal fluid (CSF) neurofilament light (NfL) and neurogranin (Ng) levels are associated with cognitive decline and may be useful markers of neurodegeneration. However, to our knowledge, previous studies have not assessed these CSF markers in the community, evaluated them with regards to risk of mild cognitive impairment (MCI), or compared their prognostic value with CSF total tau (T-tau) or phosphorylated tau (P-tau). Objective: To determine (1) whether CSF NfL and Ng levels were associated with risk of MCI, (2) the effect size of these markers compared with CSF T-tau or P-tau for risk of MCI, and (3) whether CSF amyloid-β (Aβ42) modified these associations. Design, Setting and Participants: The analyses included 648 participants without cognitive impairment who were enrolled into the prospective population-based Mayo Clinic Study of Aging between January 2004 and December 2015 with available CSF data and at least 1 follow-up visit. Participants were followed up for a median of 3.8 years (interquartile range, 2.6-5.4 years). The CSF NfL and Ng levels were measured using an in-house sandwich enzyme-linked immunosorbent assay. The CSF Aβ42, T-tau, and P-tau levels were measured with automated electrochemiluminescence immunoassays. Cox proportional hazards models, with age as the timescale, were used to assess the association between CSF NfL, Ng, Aβ42, T-tau, or P-tau with risk of MCI after adjusting for sex, education, apolipoprotein E genotype, and the Charlson comorbidity index. To examine CSF Aβ42 as an effect modifier, it was categorized into tertiles; the bottom tertile was defined as having elevated brain amyloid. Main Outcomes and Measures: Risk of MCI. Results: At baseline, the median age of the 648 participants without cognitive impairment was 72.3 years (range, 50.7-95.3 years) and 366 (56.5%) were men; 96 (14.8%) developed incident MCI. Compared with the bottom quartile, the top quartile of CSF NfL was associated with a 3.1-fold increased risk of MCI (hazard ratio, 3.13; 95% CI, 1.36-7.18) in multivariate models. Neither CSF T-tau, P-tau, nor Ng was associated with risk of MCI. There was no interaction between Aβ42 and CSF NfL for risk of MCI. Conclusions and Relevance: Elevated CSF NfL levels but not CSF T-tau, P-tau or Ng are a risk factor for MCI in a community population and are independent of brain amyloid.
Authors: Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan Journal: Lancet Neurol Date: 2013-09-04 Impact factor: 44.182
Authors: Ineke A van Rossum; Stephanie J B Vos; Leah Burns; Dirk L Knol; Philip Scheltens; Hilkka Soininen; Lars-Olof Wahlund; Harald Hampel; Magda Tsolaki; Lennart Minthon; Gilbert L'italien; Wiesje M van der Flier; Charlotte E Teunissen; Kaj Blennow; Frederik Barkhof; Daniel Rueckert; Robin Wolz; Frans Verhey; Pieter Jelle Visser Journal: Neurology Date: 2012-09-26 Impact factor: 9.910
Authors: Ozioma C Okonkwo; Michael L Alosco; H Randall Griffith; Michelle M Mielke; Leslie M Shaw; John Q Trojanowski; Geoffrey Tremont Journal: Arch Neurol Date: 2010-06
Authors: Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber Journal: World J Biol Psychiatry Date: 2017-10-27 Impact factor: 4.132
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Lorenzo Gaetani; Kina Höglund; Lucilla Parnetti; Fani Pujol-Calderon; Bruno Becker; Paolo Eusebi; Paola Sarchielli; Paolo Calabresi; Massimiliano Di Filippo; Henrik Zetterberg; Kaj Blennow Journal: Alzheimers Res Ther Date: 2018-01-23 Impact factor: 6.982
Authors: Shreyasee Das; Nele Dewit; Dirk Jacobs; Yolande A L Pijnenburg; Sjors G J G In 't Veld; Salomé Coppens; Milena Quaglia; Christophe Hirtz; Charlotte E Teunissen; Eugeen Vanmechelen Journal: Int J Mol Sci Date: 2022-06-29 Impact factor: 6.208
Authors: Michelle M Mielke; Jeremy A Syrjanen; Kaj Blennow; Henrik Zetterberg; Ingmar Skoog; Prashanthi Vemuri; Mary M Machulda; Jonathan Graff-Radford; David S Knopman; Clifford R Jack; Ronald C Petersen; Silke Kern Journal: Alzheimers Dement Date: 2019-10-23 Impact factor: 21.566
Authors: Katheryn A Q Cousins; Jeffrey S Phillips; David J Irwin; Edward B Lee; David A Wolk; Leslie M Shaw; Henrik Zetterberg; Kaj Blennow; Sarah E Burke; Nikolas G Kinney; Garrett S Gibbons; Corey T McMillan; John Q Trojanowski; Murray Grossman Journal: Alzheimers Dement Date: 2020-11-23 Impact factor: 21.566
Authors: Michelle M Mielke; Scott A Przybelski; Timothy G Lesnick; Silke Kern; Henrik Zetterberg; Kaj Blennow; David S Knopman; Jonathan Graff-Radford; Ronald C Petersen; Clifford R Jack; Prashanthi Vemuri Journal: Alzheimers Dement Date: 2021-03-04 Impact factor: 16.655
Authors: Omar H Butt; Justin M Long; Rachel L Henson; Elizabeth Herries; Courtney L Sutphen; Anne M Fagan; Carlos Cruchaga; Jack H Ladenson; David M Holtzman; John C Morris; Beau M Ances; Suzanne E Schindler Journal: Neurobiol Aging Date: 2021-02-11 Impact factor: 5.133